

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 February 2006 (16.02.2006)

PCT

(10) International Publication Number
WO 2006/015490 A1

(51) International Patent Classification⁷:
27/54, A61F 2/14, G02B 1/00

(74) Agents: WHITE, Stephanie, R. et al.; Osler, Hoskin & Harcourt LLP, Suite 1500, 50 O'Connor Street, Ottawa, Ontario K1P 6L2 (CA).

(21) International Application Number:

PCT/CA2005/001240

(22) International Filing Date: 12 August 2005 (12.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/601,270 13 August 2004 (13.08.2004) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GRIFFITH, May [CA/CA]; R.R.#3, 1006 Spruce Ridge Road, Carp, Ontario K0A 1L0 (CA). CARLSSON, David, J. [CA/CA]; 14 Delong Drive, Ottawa, Ontario K1J 7E6 (CA). LI, Fengfu [CA/CA]; 19 Maxton Private, Ottawa, Ontario K1J 1J1 (CA). LIU, Yuwen [CA/CA]; 514--790 Springfield Drive, Ottawa, Ontario K1V 6L2 (CA). ASMANRAFAT, Merhdad [CA/CA]; 112 Robert-Stewart Road, Gatineau, Québec J9H 7K7 (CA).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OPHTHALMIC DEVICES AND RELATED METHODS AND COMPOSITIONS

(57) Abstract: Devices, methods, and compositions for improving vision or treating diseases, disorders or injury of the eye are described. Ophthalmic devices, such as corneal onlays, corneal inlays, and full-thickness corneal implants, are made of a material that is effective in facilitating nerve growth through or over the device. The material may include an amount of collagen greater than 1% (w/w), such as between about 10% (w/w) and about 30% (w/w). The material may include collagen polymers and/or a second biopolymer or water-soluble synthetic polymer cross-linked using EDC/NHS chemistry. The material may additionally comprise a synthetic polymer. The devices are placed into an eye to correct or improve the vision of an individual or to treat a disease, disorder or injury of an eye of an individual.

OPHTHALMIC DEVICES AND RELATED METHODS AND COMPOSITIONSCROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit of U.S. Provisional Application No. 60/601,270, filed August 13, 2004, the entire contents of which are hereby incorporated by reference.

BACKGROUND OF THE INVENTION

10 1. Field of the invention

The present invention relates to devices, methods, and compositions for enhancing the vision of an individual or for treating a traumatic injury of an eye or an ophthalmic disease or disorder in an individual. In particular, the invention 15 relates to corneal onlays, corneal inlays, and corneal implants that are made of a material that provides one or more benefits to the individual.

2. Description of related art

U.S. Pat. No. 5,713,957 discloses corneal onlays which 20 comprise a non-biodegradable non-hydrogel ocularly biocompatible material, and having a porosity sufficient to allow passage through the onlay of tissue fluid components having a molecular fluid weight greater than 10,000 Dalton.

U.S. Pat. No. 5,716,633 discloses a collagen/PHEMA-25 hydrogel for promoting epithelial cell growth and regeneration of the stroma. The collagen-hydrogel may be provided as an optical lens to be affixed to Bowman's membrane, which is effective to promote and support epithelial cell growth or attachment of the corneal epithelium over the anterior surface 30 of the lens. The collagen-hydrogel is a hydrogel polymer formed by the free radical polymerization of a hydrophilic monomer solution gelled and cross-linked in the presence of an aqueous stock solution of collagen to form a three dimensional polymeric meshwork for anchoring collagen. The final

concentration of collagen in the onlay is from about 0.3% to about 0.5% (wt/wt).

U.S. Pat. No. 5,836,313 discloses methods for forming implantable composite keratoprostheses. The methods provide 5 keratoprostheses designed to provide a suitable substrate for corneal epithelial cell growth. The keratoprostheses are formed by placing corneal tissue in a mold having a corneal implant shape and cross-linking a polymeric solution to chemically bond a biocompatible hydrogel having a thickness 10 between approximately 50 and 100 microns to the corneal tissue to form the keratoprosthesis. Or, a polymer solution is placed between the corneal tissue and a pre-formed hydrogel and then polymerized so that the polymer solution couples to both the hydrogel and the corneal tissue

15 U.S. Pat. No. 6,454,800 discloses a corneal onlay or corneal implant that comprises a surface with a plurality of surface indentations that supports the attachment and growth of tissue cells.

U.S. Pat. No. 6,689,165 discloses a synthetic device for 20 cornea augmentation and replacement that increases corneal epithelium cell adhesion and migration using tethered corneal enhancer agents.

Some problems associated with existing collagen-based materials are that the collagen based materials are not 25 optically clear, which may be due to the formation of, or conversion into, a fibrous based material, which results in undesirable light scattering.

Thus there remains a need for materials which are biocompatible, ophthalmically acceptable, and are suitable for 30 placement in an eye to enhance an individual's vision.

SUMMARY OF THE INVENTION

An ophthalmic device comprises a body including a composition effective in facilitating nerve growth through or

over the body when the device is placed in an eye of an individual. In certain embodiments, the device is a vision enhancing ophthalmic device. In alternative embodiments, the device is a therapeutic ophthalmic device. The present vision 5 enhancing devices can be understood to be devices that are structured to correct one or more refractive errors. In other words, the present devices can be understood to be refractive error correcting devices. The body of the present devices can be formed to have an optical power.

10 The composition of the present invention is optically clear and may comprise an amount of collagen between about 1% (w/v or w/w) and about 50% (w/v or w/w). In certain embodiments, the amount of collagen is greater than 2.5% (w/w or w/v). As used herein, the amount of collagen and/or other 15 components of the compositions and devices will be understood to be either w/w or w/v percentages without departing from the spirit of the invention. In additional embodiments, the amount of collagen is greater than about 5.0%. For example, the material may comprise an amount of collagen between about 20 10% and about 30%. In certain embodiments, the material comprises an amount of cross-linked collagen between about 1% and about 50%, wherein the collagen is cross-linked using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC; CAS # 1892-57-5) and N-hydroxysuccinimide. In further embodiments, the 25 amount of cross-linked collagen is between 2.5% and about 50%. The material may comprise a first collagen polymer cross-linked to a second collagen polymer. In certain embodiments, the ophthalmic devices disclosed herein are manufactured without glutaraldehyde. For example, the ophthalmic devices 30 do not utilize glutaraldehyde as a cross-linker in the manufacture thereof. Glutaraldehyde may not be desirable or preferred to use as a cross-linking agent due to handling and safety requirements for glutaraldehyde and/or the present compositions and devices. In certain embodiments, the

ophthalmic devices are manufactured without cytotoxic components, or in other words, are manufactured using components having a reduced cytotoxicity.

5 The foregoing device may be a corneal onlay, a corneal inlay, or a full-thickness corneal implant, such as a device configured to replace an individual's natural cornea. The present devices are transparent, and may be produced from compositions which are transparent before the compositions are formed into the devices.

10 The material of the foregoing device may also comprise one or more cell growth enhancer agents or one or more additional biopolymers.

15 A method of making an ophthalmic device, such as a refractive error correcting device, in accordance with the disclosure herein comprises cross-linking collagen polymers using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide (EDC and NHS). The cross-linking occurs at an acidic pH, such as a pH of about 5.0 to about 5.5. The method may also comprise one or more steps of adding a cell 20 growth enhancer agent to the cross-linked composition. The method comprises placing the composition in a mold, and allowing the composition to cure to form an ophthalmic device.

25 Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. In addition, any feature or combination of features may be specifically excluded from any 30 embodiment of the present invention.

Additional advantages and aspects of the present invention are apparent in the following detailed description, drawings, examples, and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of a sectional view of a T-piece adapter of a system for producing the present compositions and devices.

5 FIG. 2 is an illustration of a sectional view of a female Luer adapter of a system for producing the present compositions and devices.

10 FIG. 3 is a plan view of the T-adapter of FIG. 1 with a septum and two syringes coupled thereto to produce the present compositions and devices.

FIG. 4 is a graph of cell count as a function of time for a human recombinant hydrogel material designated F1.

FIG. 5 is a graph of cell count as a function of time for a human recombinant hydrogel material designated F3.

15 FIG. 6 is a graph of cell count as a function of time for a human recombinant hydrogel material designated F6.

FIG. 7 is a photograph of a human recombinant hydrogel material designated F3 located in a rat.

20 FIG. 8 is an illustration of one embodiment of the present refractive error correcting ophthalmic devices.

FIG. 8A is an illustration of a lens edge configuration of one embodiment of the present onlays.

FIG. 9 is a graph of swell ratio as a function of EDC to NH₂ mole ratio.

25 FIG. 10 is a graph of tensile strength as a function of EDC to NH₂ mole ratio.

FIG. 11 provides graphs of tensile strength as a function of collagen concentration (left panel) and swelling ratio as a function of collagen concentration (right panel).

30 FIG. 12 provides graphs of heat flow as a function of temperature for compositions having different EDC to NH₂ mole ratios (left panel), and heat flow as a function of temperature for compositions having different CSC concentrations (right panel).

FIG. 13 is a graph of neurite length as a function of chondroitin sulfate to collagen dry weight ratio.

DETAILED DESCRIPTION

5 A typical human eye has a lens and an iris. The posterior chamber is located posterior to the iris and the anterior chamber is located anterior to iris. The eye has a cornea that consists of five layers, as discussed herein. One of the layers, the corneal epithelium, lines the anterior 10 exterior surface of cornea. The corneal epithelium is a stratified squamous epithelium that extends laterally to the limbus.

The five layers of the cornea include the corneal epithelium, the Bowman's membrane, the stroma, Descemet's 15 membrane, and the endothelium. The corneal epithelium usually is about 5-6 cell layers thick (approximately 50 micrometers thick), and generally regenerates when the cornea is injured. The corneal epithelium provides a relatively smooth refractive surface and helps prevent infection of the eye. The corneal 20 stroma is a laminated structure of collagen which contains cells, such as fibroblasts and keratocytes, dispersed therein. The stroma constitutes about 90% of the corneal thickness. The anterior portion of the stroma, which underlies the epithelium, is acellular and is known as Bowman's membrane. 25 Bowman's membrane is located between the epithelium and the stroma and is believed to protect the cornea from injury. The corneal endothelium typically is a monolayer of low cuboidal or squamous cells that dehydrates the cornea by removing water from the cornea. An adult human cornea is typically about 500 30 μm (0.5 mm) thick and is typically devoid of blood vessels.

Ophthalmic devices have been invented which provide one or more benefits to an individual, such as a person, who desires their vision to be enhanced or improved or who is in need of treatment of a disease, disorder or traumatic injury

of the eye. The devices described herein may be configured as corneal onlays, corneal inlays, or full-thickness corneal implants. The present devices may enhance vision of an individual who has reduced vision or provide vision to an 5 individual who has no vision. The devices described herein specifically exclude intraocular lenses.

As used herein, "optically clear" refers to at least 85% transmission of white light. In certain embodiments, "optically clear" refers to optical clarity that is equivalent 10 to that of a healthy cornea, for example, having greater than 90% transmission of white light and less than 3% scatter.

As used herein, a "corneal onlay" is an ophthalmic implant or device configured, such as sized and shaped, to be located between the epithelium or an epithelial cell layer and 15 Bowman's membrane of an individual's eye, such as a human's or animal's eye. In comparison, a contact lens is configured to be located over the epithelium of an eye. A corneal onlay may thus rest entirely over the Bowman's membrane, or it may include one or more portions that extend into Bowman's 20 membrane. Such portions constitute a minor portion of the device, such as less than 50% of the area or volume of the device.

As used herein, a "corneal inlay" is a device or implant configured to be placed in the stroma of an eye. Corneal inlays may be placed in the stroma by forming a flap or a 25 pocket in the stroma. Corneal inlays are placed below the Bowman's membrane of an eye.

As used herein, a "full-thickness corneal implant", refers to a device that is configured to replace all or part 30 of an unhealthy cornea of an eye located anterior to the aqueous humor of the eye.

The present ophthalmic devices have a reduced cytotoxicity or are non-cytotoxic and provide one or more benefits to an individual in which the device is placed. For

example, the devices provide one or more of the following: (i) a desired refractive index, (ii) a desired optical clarity (for visible light, optical transmission and light scattering equal to or better than those of healthy human cornea material of comparable thickness), (iii) a desired optical power, such as a vision enhancing optical power, (iv) enhanced comfort, (v) enhanced corneal and epithelial health, and (vi) therapeutic benefit, for example, in the treatment of a disease, disorder or traumatic injury of an eye. The present 10 ophthalmic devices are transparent or are formed of a transparent material. Some examples of such devices include devices which are optically clear.

The foregoing benefits, as well as others, may be obtained by forming the device of a material that is (i) 15 shapeable, such as moldable, to form a matrix with an acceptable optical power, (ii) optically clear or visually transparent, and (iii) effective in facilitating nerve growth through and/or over the device. When the device is a corneal onlay, the device is effective in facilitating re-20 epithelialization over the anterior surface of the device.

The device is formed of a material that has sufficient mechanical or structural properties to survive handling, implantation, which may include suturing, and post-installation wear and tear. The device provides or permits 25 sufficient nutrient and gas exchange to promote a healthy eye. The devices that are produced in molds, such as corneal onlays, are formed of a material which can be molded to the appropriate size and shape, including edge gradient and vision corrective curvature, as discussed herein.

30 In one embodiment of the present invention, a vision enhancing ophthalmic device comprises a body including a material that is effective in facilitating nerve growth through the body when the device is placed in an eye of an individual. By facilitating nerve growth through the body,

corneas of individuals receiving the device or devices maintain their touch sensitivity. The body is formed to have an optical power. Thus, the body may be understood to be a lens body. As discussed herein, the device may be configured, 5 such as sized and shaped, to be a corneal onlay, a corneal inlay, or a full-thickness corneal implant. In certain embodiments, the present refractive error correcting devices may not have an optical power. For example, refractive error correcting devices in accordance with the present disclosure 10 may be understood to be blanks that can be placed between a patient's corneal epithelium and Bowman's membrane, or in the patient's corneal stroma.

For corneal onlays, the material from which the onlay is produced provides for or permits gas and nutrient, such as 15 glucose, exchange between the Bowman's membrane and epithelium to maintain a viable, fully functioning epithelium. Other nutrients include factors or agents to promote or enhance the survival, growth, and differentiation of cells, such as epithelial cells. The exchange should be comparable to or 20 better than that of a healthy human cornea. The permeability of the material to nutrients and/or drugs may be monitored using conventional techniques. In addition, the movement of the nutrients and/or drugs through the material should not cause the optical properties of the material to change. The 25 onlays or lenticules are fully biocompatible, allow rapid epithelial adhesion to the onlay, and permit restoration of nerve innervation and sensitivity, for example touch sensitivity.

The present ophthalmic devices may comprise an 30 extracellular matrix (ECM) component. In certain devices, the material of the body comprises, consists essentially of, or consists of, collagen. The collagen may be cross-linked, for example by using EDC/NHS in the manufacture of the devices. The amount of collagen provided in the present hydrogel

devices is greater than what is currently used in other ophthalmic devices. For example, the amount of collagen provided in the present devices is typically greater than 1% (w/w) or (w/v), as discussed herein. In certain embodiments, 5 the amount of collagen is greater than 2.5%. For example, the amount of collagen may be about 5.0% or more. In certain embodiments of the present devices, the amount of collagen is between about 1% (w/w) and about 50% (w/w), such as from between 2.5% and about 50%. For example, the amount of 10 collagen is greater than about 6% (w/w). Or, the material may comprise an amount of collagen between about 10% (w/w) and about 30% (w/w). As understood by persons of ordinary skill in the art, about 15 wt% of a hydrated human cornea is collagen (Maurice D M: The Cornea and Sclera, pp489-600. The 15 Eye, Vol I, Second ed., Ed. H Davson. Academic Press, New York, 1969). Thus, the present devices include an amount of collagen that is greater than existing ophthalmic devices and is much more similar to the amount of collagen present in human corneas. In addition, the amount and type of collagen 20 provided in the present devices is effective in providing a desired refractive index, a desired optical clarity, shapability, permitting handling, implantation, and suturing of the device in the eye, and post-installation wear and tear.

The remaining portion of the ophthalmic device, such as 25 the non-collagen based portion, may be a liquid, such as water or saline, or may also include one or more additional polymers, such as biopolymers and the like. For example, an ophthalmic device which comprises about 24% (w/w) collagen, as disclosed herein, may include about 76% (w/w) of a liquid, such as water or saline. In other words, in a hydrated state, 30 the ophthalmic device may have a collagen component that is 24% of the weight of the hydrated ophthalmic device. As another example, an ophthalmic device may comprise a collagen component that is 24% of the weight of the hydrated device,

and a second polymeric component that is 6% of the weight of the hydrated device, and 70% of the weight is a liquid.

As understood by persons of ordinary skill in the art, in the unhydrated state, the amount of collagen in the device may 5 be a greater percentage than in the hydrated state.

Collagen comprises three polypeptide chains and is helical in structure. As used herein, the term "collagen polymer" is intended to refer to a triple helical collagen molecule. Collagen is a rod-like molecule with a length and 10 diameter of about 300 nm and about 1.5 nm, respectively. A collagen molecule has an amino acid sequence called a "telopeptide" on both its N- and C-terminals, which include most of the antigenicity of collagen. Atelocollagen is obtained by pepsin digestion [DeLustro *et al.*, *J Biomed Mater Res.* 1986 Jan;20(1):109-20] and is free from telopeptides, 15 indicating that it has low immunogenicity [Stenzel *et al.*, *Annu Rev Biophys Bioeng.* 1974;3(0):231-53].

The collagen used in the above-identified devices may be obtained or derived from any suitable source of collagen 20 including animal, yeast, and bacterial sources. For example, the collagen may be human collagen, bovine collagen, porcine collagen, avian collagen, murine collagen, equine collagen, among others, or the collagen may be recombinant collagen. Recombinant collagen in the present devices can include one or 25 more structural or physical features that are not present in collagen obtained from normal animal sources since recombinant collagen is obtained from bacteria, yeast, plants or transgenic animals. For example, recombinant human collagen can include different glycosylation components that may not be present in animal-derived and processed collagen. In addition, recombinant collagen can have different degrees of cross-linking relative to animal derived collagen, which can 30 be of variable composition. Variation in cross-linking degrees in animal derived collagens can result in

inconsistencies and variable chemical and physical properties of the collagen that may not be desirable. As well as being of tightly controlled purity, recombinant human collagen is not associated with viral and/or prion contamination, which 5 may be associated with animal derived collagen. Collagen useful in the present devices is publicly available or can be synthesized using conventional techniques. For example, recombinant collagen may be obtained from Fibrogen (from mutigene yeast bioreactor culture) or Pharming (Netherlands) 10 (from the milk of transgenic cows or rabbits), or recombinant collagen may be prepared and obtained using the methods disclosed in PCT Publication No. WO 93/07889 or WO 94/16570. In certain devices, the collagen may be type I collagen. The devices may also be made of atelocollagen (e.g., collagen 15 without telopeptides). In certain embodiments, the collagen is a non-denatured type of collagen. Atelocollagen may be obtained from companies such as Koken Japan (Supplier A, as used herein), in which bovine collagen is available as 3.5% (w/v) in a neutral composition, 3.0% (w/v) in an acidic composition, 10% (w/v) in an acidic composition, and in which porcine collagen is available as 3.0% (w/v) in an acidic composition, or as acidic, freeze dried porcine collagen powder. Acidic, freeze dried porcine collagen powder may also 20 be obtained from Nippon Ham (Japan) (Supplier B, as used herein). Becton Dickinson (Supplier C, as used herein) provides 0.3% acidic and 10% acidic collagen compositions. 25

Of the several collagen types, atelocollagen I provides for ease of solution, handling and final device clarity. This collagen (bovine, porcine or recombinant, either in neutral or 30 acidic solution, or as an acidic, freeze-dried powder) is available from several companies, as described above. Freeze dried, acidic porcine collagen dissolves readily to give homogenous (non-opalescent) aqueous solutions in cold water at up to 33% (w/v) concentration by stirring at 4°C. The pH of

these clear collagen compositions, such as solutions, is about 3 (Supplier B) or about 5 (Supplier A). Commercial acidic collagen compositions as low as 0.3% (w/v), can be concentrated by vacuum evaporation with stirring at 0° - 4°C 5 to give clear solutions of up to about 10% (w/v) final collagen concentration, which may then be used in the manufacture of the present devices.

Relatively tough or strong ophthalmic devices may be obtained using collagen type I that has not been denatured 10 (i.e. lost all or a substantial portion of its triple helix conformation to become gelatin) during isolation and purification.

Differential scanning calorimetry (DSC) is a useful tool to determine the quality of solutions of suppliers' collagen 15 based on their triple helix content (Table 1). For near perfect triple helix content, the DSC enthalpy of denaturing ($\Delta H_{\text{denature}}$) is in the 65 - 70 J/g range (based on the dry collagen weight). From DSC data, $\Delta H_{\text{denature}}$ results indicate that solutions from commercial, acidic, freeze dried, porcine 20 collagens and some of the commercial, bovine collagen solutions are in the fully, triple helix form.

Collagen solutions with low triple helix content ($\Delta H_{\text{denature}} < 5$ J/g, supplier C, Table 1) have relatively low viscosity and give weak gels as compared to compositions or solutions of 25 the same concentration from collagens with close to 100% triple helix content. Collagen compositions (solutions) with $\Delta H_{\text{denature}} >$ about 60 J/g were found to make acceptable ophthalmic devices.

30 **Table 1. Enthalpy of denaturing of collagen solutions**

Commercial collagen samples	Composition	$\Delta H_{\text{denature}}$ (J/g of dry collagen)
Koken (Japan), Supplier A	10% bovine solution	65.3
Koken (Japan), Supplier A	10% bovine	67.5

	collagen solution, concentrated from 3% acidic	
Koken (Japan), Supplier A	5% bovine collagen solution, concentrated from 3.0% acidic	66.4
Koken (Japan), Supplier A	3.5% bovine neutral solution	68.1
Koken (Japan), Supplier A	3.5% bovine neutral solution, after heat denaturing	24.4
Koken (Japan), Supplier A	3.0% porcine collagen solution	72.0
Koken (Japan), Supplier A	5% Solution from freeze dried, porcine collagen (acidic)	68.1
Nippon Ham, Supplier B	10% Solution from freeze dried, porcine collagen (very acidic)	63.4
Becton Dickinson, Supplier C	5% bovine solution concentrated from 0.3%	59.4
Becton Dickinson, Supplier C	"10%" bovine solution	4.8
FibroGen recombinant human collagen	10% solution, concentrated from 0.3 wt/wt%	67.7

In certain embodiments, including those described above, the material of the body may comprise a collagen polymers that are cross-linked. Or, stated differently, the material of the body may comprise two or more cross-linked collagen polymers. For example, the material of the body may comprise a first collagen polymer, a second collagen polymer, and a third collagen polymer. Other materials may comprise more than three collagen polymers. The cross-linked polymers may be understood to be a collagen component of the ophthalmic device.

Thus, a vision enhancing ophthalmic device in accordance with the present invention may comprise a collagen component having an amount of collagen between about 1% (w/w) and about

50% (w/w) and being formed to have an optical power. As discussed herein, in certain embodiments, the amount of collagen is greater than 2.5%, such as at least about 5.0%. For example, in certain embodiments, the collagen is greater than about 6% (w/w). For example, the amount of collagen is between about 10% (w/w) and about 30% (w/w). For example, the amount of collagen may be between about 10% (w/w) and about 24% (w/w). In certain devices, the collagen is the sole water-swellable (e.g., hydrogel) polymer of the device. In other devices, the collagen may be the sole device or lens forming polymer. For example, the device may comprise 100% collagen in a dry state. As discussed above, in certain devices, the collagen may be cross-linked, or at least partially cross-linked, using EDC/NHS, for example.

15 The collagen polymers used in the manufacture of the compositions and devices of the present invention may be from the same collagen source or from different collagen sources. Or, stated differently, a single type of collagen, for example an atelocollagen type I (which contains a plurality of 20 collagen polymer chains), is processed in a manner effective to permit the collagen polymers to cross-link to each other. In one embodiment, the collagen polymers are recombinant collagen. In other embodiments, both the collagen polymers are derived from the same animal source. Individual collagen 25 polymers in a single composition may have different molecular weights.

It may be understood that the present refractive error correcting devices comprise cross-linked recombinant collagen. The amount of collagen present in such devices is greater than 30 that found in other collagen based refractive error correcting devices that have been previously disclosed. Such devices may be formed to have an optical power.

The devices disclosed herein are transparent. For example, the devices should be optically clear. For example,

the device should provide minimal light scattering (comparable to or better than healthy, human cornea tissue) when the device is placed in an eye of an individual. In addition, the device disclosed herein has a refractive index. In certain 5 embodiments, the refractive index is between about 1.34 and about 1.37. For example, the refractive index may be between 1.341 and 1.349. When the device is configured as a corneal onlay or corneal inlay, the device is configured to be placed in a healthy eye of an individual, as compared to an eye in 10 which the cornea is damaged or diseased where a full-thickness corneal implant may be needed. In certain embodiments of the present devices, the devices do not have a yellow tinge or a yellow color. For example, the devices may be designed to reduce or eliminate a yellow tinge or a yellow color that may 15 be associated with some collagen containing compositions.

The present device has an anterior surface and a posterior surface. Thus, the body or the collagen component of the device may have an anterior surface and a posterior surface. The anterior and posterior surfaces are generally 20 opposing surfaces. The anterior surface of the device refers to the surface that is oriented away from the retina when the device is placed in an eye, and the posterior surface is oriented toward the retina when the device is placed in an eye. When the device is a corneal onlay, the posterior surface will be adjacent to, and may contact, Bowman's 25 membrane, and the anterior surface will be adjacent to and may contact the corneal epithelium. When the device is a corneal inlay, the anterior surface will be adjacent or oriented towards the Bowman's membrane, and the posterior surface will be in the stroma oriented towards the retina of the eye. When 30 the device is a full-thickness corneal implant, the anterior surface is oriented toward the corneal epithelium, and the posterior surface is adjacent and may be in contact with the corneal endothelium.

The present device may comprise no additional surface modification, or the device may comprise a surface modification that affects cell growth and/or differentiation on either or both of the anterior and posterior surfaces. For 5 example, a corneal onlay may include no surface modification that affects cell growth on the anterior or posterior surface. As used herein, "cell growth" refers to an expansion of a cell or a population of cells. Thus, cell growth refers to the physical growth of an individual cell, such as an increase in 10 surface area, volume, and the like, proliferation of a cell or cells, such as the division of cells, and the migration of cells, in some cases to form a stratified multilayer as found on a healthy human cornea. Cell growth refers to growth of nerve cells, such as the extension of one or more neuronal 15 processes over, under or through the device, and to the growth or migration or proliferation of epithelial cells or endothelial cells over a surface of the device. As used herein, "cell differentiation" refers to the morphological, biochemical and physiological changes that a single or 20 population of totipotent, multipotent or immature precursor cells (including stem cells) undergoes to achieve its final phenotype. In certain embodiments of the present devices, epithelial cells grow over the corneal onlay and are tightly coupled thereto, for example directly attached to the onlay, 25 specifically the anterior surface of the onlay.

In certain corneal onlays, the body or collagen component includes a posterior surface modification effective in reducing epithelial cell growth under the onlay when the onlay is placed in an eye of an individual. In addition, or 30 alternatively, corneal onlays may include a body or collagen component that includes an anterior surface modification effective in promoting epithelial cell growth, including migration, over the anterior surface of the onlay when the onlay is placed in an eye of an individual. Relatedly, full-

thickness corneal implants may include a body or collagen component that includes a posterior surface modification effective in reducing endothelial cell growth over the posterior surface of the full-thickness corneal implants when 5 the implant is placed in an eye. Full-thickness corneal implants may include no anterior surface modifications.

Examples of surface modifications that may reduce cell growth include providing a plasma polymerized fluorinated monomer film, such as CF_4 or C_3F_8 on one or both of the 10 anterior and posterior surfaces, providing a low free surface energy on one or both of the surfaces, and/or by making one or both of the surfaces hydrophilic. The surfaces may be made hydrophilic by providing an alginate coating over the surface or surfaces.

15 The devices may include one or more cell growth enhancer agents that facilitate cell growth on or through the device. In certain embodiments, the cell growth enhancer agent comprises a peptide. For example, the cell growth enhancer agent may be a peptide having an amino acid sequence that 20 includes RGD, YIGSR, or IKVAV. Collagen I itself is a rich source of RGD sequences. In certain embodiments, the cell growth enhancer agent is a neurotrophic factor or its bioactive or neurotrophic portions of the molecule. For example, the neurotrophic factor may be nerve growth factor 25 (NGF), an epidermal growth factor (EGF or HB-EGF) or basic fibroblast growth factor (bFGF or FGF-2). The cell growth enhancer agent may be integrally formed with the collagen component or body of the device, or in other words, the cell growth enhancer agent may be provided substantially throughout 30 the device. In comparison, some ophthalmic devices only include peptides provided on one surface of the device.

In certain embodiments, the collagen-based ophthalmic devices comprise a collagen component which was processed at an acidic pH in the manufacture of the device. An acidic pH

is particularly useful when the collagen component comprises a first collagen polymer cross-linked to a second collagen polymer. The acidic pH used in the manufacture of such devices is typically less than about 6.0, for example, the pH 5 may be between about 5.0 and about 5.5. By maintaining an acidic pH and by preventing or reducing pH surges during pH adjustments, fibrillogenesis of the collagen is reduced. In addition, by maintaining the pH above about 5.0, the collagen does not degrade as quickly as if the pH were less than 5.0.

10 The collagen polymers may be cross-linked using any small or polymeric, collagen-reactive agent or molecule. The cross-linking chemistry may employ conventional methods which are routine to persons of ordinary skill in the art or novel reagents. By cross-linking the collagen polymers, the devices 15 maintain their optical clarity and are able to withstand biodegradation.

In certain embodiments, the collagen polymers are cross-linked using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC; CAS #1892-57-5) and N-hydroxysuccinimide (NHS). In 20 other words, a crosslinking agent used in the manufacture of the device is EDC/NHS. The collagen polymers and the EDC/NHS cross-linker are mixed together at an acidic pH while preventing surges in pH. After sufficient mixing, portions of the mixed composition are placed in a mould, and are allowed 25 to cure in the mould to form an ophthalmic device. One advantage of utilizing the water-soluble EDC/NHS chemistry to crosslink collagen and CSC is that it results in a zero length (amide) bond. This reduces the possibility of grafted toxic substances leaching out into tissues. In addition, unreacted 30 reagents and by-products from the EDC/NHS reaction are water-soluble and thus can be removed easily after gel formation.

In certain embodiments, the collagen polymers are cross-linked using a cross-linker or cross-linking agent that has a reduced cytotoxicity. Such cross-linkers preferably do not

irritate or cause a negative reaction when the ophthalmic devices are placed in an eye of an individual. In some embodiments, the cross-linker is a cross-linker other than glutaraldehyde. Although glutaraldehyde may be a useful 5 cross-linker in certain embodiments, glutaraldehyde may not be preferred due to handling and safety requirements.

In additional embodiments, the process may further comprise using at least one of the following components: poly(N-isopropylacrylamide-co-acrylic acid), a chondroitin 10 sulfate, a keratan sulfate, a dermatan sulphate, elastin, chitosan, N,O-carboxymethylchitosan, hyaluronic acid, hyaluronic acid aldehyde, and alginate, which may be mixed with the collagen compositions. Thus, the ophthalmic devices may comprise a collagen component, such as a matrix of cross-linked collagen polymers, and one or more non-collagen 15 polymers, including biopolymers. The non-collagen polymers may be cross-linked together and/or may be cross-linked to the collagen polymers to form a network or matrix of cross-linked polymers.

20 In certain embodiments, the compositions are mixed together through relatively narrow channels or passageways to induce a high shear between the different compositions. In one embodiment, the compositions are mixed using a syringe-based system. The mixing depends on the syringe pumping 25 through narrow channels to induce high shear between the viscous collagen solution and the reagents. The channel diameter is chosen to accommodate the viscosity and burst strength of the syringes or other similar devices. For high viscosities (e.g., 20-30% (w/v) collagen solutions), small 30 volume syringes with small diameter syringe plungers are used because higher pressures can be obtained by hand. The mixing occurs at an acidic pH, such as between about 5.0 and about 5.5 and at a reduced temperature, such as between about 0°C and about 5°C.

Compared to other ophthalmic devices, the present devices are manufactured without the use of living cells. Thus, the present inventors have invented new methods of manufacturing compositions and ophthalmic devices with relatively high, and 5 nearly physiological concentrations, of collagen without using living corneal cells. In addition, the present devices are substantially or entirely free of a synthetic dendrimer component, which has been used to increase the cross-reactivity of collagen in other devices.

10 Additional nerve-friendly materials may be used in the manufacture of the present devices. Such materials may be manufactured using the methods disclosed herein and tested for nerve-friendliness, such as nerve growth, using conventional methods which are routine to persons of ordinary skill in the 15 art, such as cell culture systems, and the like. For example, the materials can be tested and identified using the methods disclosed in WO 2004/015090, filed August 11, 2003.

20 The devices disclosed herein are configured, such as sized and shaped, to be placed in an eye around the corneal region of the eye. When the device is a corneal onlay, the onlay may have a diameter from about 4 mm to about 12 mm, such as about 6 mm. The onlay may also have an edge thickness less than about 30 μm , for example, between about 10 μm and about 30 μm . The onlay may also have a center thickness of about 70 25 μm .

Onlay shaped moulds may be manufactured from polypropylene and may have diameters of 4 mm, 6 mm, 8 mm, or 12 mm. The moulds should be relatively stiff (e.g., non-flexing during closure), and transparent for allowing charge 30 visualization. The moulds are configured to provide a fine taper (e.g., about 10 μm) onlay edge, or a somewhat steeper (e.g., about 30 μm) onlay edge.

Corneal implant moulds (either full-thickness or partial-thickness) may have diameters of about 12 mm. The transplant

moulds are shaped with a desired curvature and thickness of the cornea. If necessary, the ophthalmic device (e.g., hydrogel) can be trephined out as needed for the transplantation procedure.

5 An example of one of the present refractive error correcting devices is illustrated in FIG. 8 and FIG. 8A.

The corneal onlays disclosed herein may also be configured to correct for one or more wavefront aberrations of an individual's eye. A description of wavefront technology 10 and the measurements of wavefront aberrations is provided in U.S. Pat. No. 6,086,204 (Magnate) and WO 2004/028356 (Altmann). The corneal onlays may be shaped to correct for a wavefront aberration by shaping the mould in a desired configuration which permits the onlay to assume the corrective 15 shape. Methods of using wavefront aberration measurements in corneal onlays is disclosed in U.S. Application No. 60/573,657, filed May 20, 2004. The onlays may also be ablated to correct for a wavefront aberration. For example, the onlays may be ablated using a laser or laser-like device, 20 a lathe, and other suitable lens shaping devices.

The corneal onlays disclosed herein may also include a plurality of different zones. For example, the corneal onlay may include an optic zone and a peripheral zone. Typically, the optic zone is bounded by the peripheral zone, or in other 25 words, the optic zone is generally centrally located about an optical axis, such as a central optical axis, of the onlay and the peripheral zone is disposed between an edge of the optic zone and the peripheral edge of the corneal onlay. Additional zones and onlay configurations may be provided with the onlay 30 depending on the particular visual deficiency experienced by the patient.

In addition, the present corneal onlays may have junctionless zones, such as two or more zones that do not have a visually or optically detectable junction. The zones of the

onlays may be smooth and continuous, and the onlays may be optically optimized to correct not only refractive errors, but also other optical aberrations of the eye and/or the optical device independently or in combination with correcting refractive errors. As understood by persons skilled in the art, a corneal onlay may be structured to correct visual deficiencies including, and not limited to, myopia, hyperopia, astigmatism, and presbyopia. The onlay may enhance or improve visual deficiencies by either optical means or physical means imposed on the stroma of the eye, or a combination thereof. Thus, the corneal onlay may be a monofocal lens or a multifocal lens, including, without limitation, a bifocal lens.

In addition, or alternatively, the corneal onlay may be a toric lens. For example, the onlay may include a toric region which may be effective when placed on an eye with an astigmatism to correct or reduce the effects of the astigmatism. The onlay may include a toric region located on the posterior surface of the onlay, or the onlay may include a toric region located on the anterior surface. Advantageously, toric onlays may be used without requiring a ballast to maintain proper orientation of the onlay on the eye since the onlay may be held in a relatively fixed position by the epithelium of the appliance. However, a ballast may be provided if desired. In certain embodiments, the onlay may include a ballast, such as a prism, or it may include one or more thinned regions, such as one or more inferior and/or superior thin zones. In onlays configured to correct presbyopia, the onlay may include one or more designs, such as concentric, aspheric (either with positive and/or negative spherical aberration), diffractive, and/or multi-zone refractive.

The present invention also encompasses compositions, such as synthetic or non-naturally occurring compositions. The

compositions may be fully or partially synthetic. For example, the invention relates to compositions that are optically clear. Such compositions may be used in the manufacture of one or more ophthalmic devices disclosed 5 herein. Alternatively, the compositions could be used in non-ophthalmic settings as non-ophthalmic compositions, or can be used in ophthalmic settings and not provide a refractive error correction. In another embodiment, a composition, in accordance with the present disclosure, comprises an amount of 10 collagen that is greater than about 1% (w/w) in a hydrated state and is optically clear. As discussed herein, the amount of collagen may be greater than 2.5%, such as at least about 5.0%. For example, the composition may comprise an amount of collagen between about 1% (w/w), or 2.5%, or about 15 5.0% and about 30% (w/w) in a hydrated state. In certain embodiments, the composition may comprise about 6% (w/w) of collagen. In other embodiments, the composition may comprise an amount of collagen between about 10% (w/w) and about 24% (w/w). The composition may comprise an amount of cross-linked 20 collagen that is greater than about 1% (w/w) in a hydrated state, wherein the collagen is cross-linked using EDC/NHS.

The present compositions may comprise two or more collagen polymers. In certain embodiments, the compositions comprise a first collagen polymer cross-linked to a second 25 collagen polymer as described above. The compositions may be substantially or completely free of cytotoxic agents, such as glutaraldehyde.

The ophthalmic devices disclosed herein may be placed in an eye using any suitable methodology or technique.

30 For example, corneal onlays may be placed over the Bowman's membrane of an eye by removing or separating a portion of the epithelium from the Bowman's membrane. In certain situations, an amount of alcohol, such as ethanol, may be applied to the corneal epithelium to delaminate the

epithelium from the eye. The alcohol may be at a concentration of about 10% to about 60%, for example about 20% or about 50%. Warming the ethanol to about 37°C (e.g., body temperature) may be effective to enhance the epithelial removal. This deepithelial technique is similar to the LASEK technique that is currently being practiced.

In other situations, a corneal onlay may be placed over Bowman's membrane by placing the onlay under an epithelial flap or in an epithelial pocket. Such flaps and pockets may be made using a cutting instrument, a blunt dissection tool, and the like. Examples of methods of placing a corneal onlay in an eye are disclosed in U.S. Application No. 10/661,400, filed September 12, 2003, and U.S. Application No. 60/573,657, filed May 20, 2004.

Corneal inlays may be placed in an eye by forming a intrastromal pocket or a corneal flap, and placing the inlay in the pocket or under the flap.

Full-thickness corneal implants may be placed in an eye by removing a damaged or diseased portion of a cornea and placing the corneal implant in or near the region of the removed portion of the cornea.

The ophthalmic devices disclosed herein may be placed in an eye using forceps, or any other suitable inserter, such as those described in U.S. Application No. 10/661,400, filed September 12, 2003, and U.S. Application No. 60/573,657, filed May 20, 2004.

To facilitate placement of the ophthalmic device in the eye, the device may include a visualization component. The visualization component can be any suitable feature that permits the device to be easily seen while being inserted or placed in an eye. For example, the visualization component may include one or more markings, which may also help with the rotational position of the device, or the visualization

component may include a dye, such as a biocompatible or non-cytotoxic dye, or a tinting agent.

Additional details regarding the present ophthalmic devices and related methods of manufacturing and using the 5 devices are provided in the examples below, which are provided by way of illustration, and do not limit the invention.

EXAMPLES

Example 1

10 Preparation of collagen-based corneal onlays.

Typically, 0.5 mL - 2.0 mL of a collagen solution in an aqueous buffer was mixed with 0.01 mL - 0.50 mL of a cross-linker agent in the aqueous buffer at about 0°C without air 15 bubble entrapment. In some compositions, a second biopolymer other than collagen was added to the composition.

To mix the compositions, syringes containing the compositions were connected to a Tefzel Tee-piece (Uptight Fittings), forming a micro-manifold that allowed thorough 20 mixing of the viscous collagen solution and/or controlled neutralization without surges in pH. A pH surge often led to irreversible fibrillogenesis of the collagen to give opaque matrices.

More specifically, a first Luer adaptor was used to 25 retain a septum, cut to size to fit tightly into the bottom of the Tee's thread hole. Septa were cut to size from Restek Corporations's, "Ice Blue" 17 mm general purpose 22397 septa. A first syringe with a buffer solution, such as MES (2-[N-morpholino]ethanesulfonic acid) buffer was locked into the 30 second Luer adaptor and any air bubbles were pushed out with the buffer solution. A collagen solution was placed in a second syringe which was then connected to the third Luer adaptor of the Tefzel Tee-piece (as shown in FIG. 1) fitted

with three Luer adaptors (FIG. 2). The full assembly is shown in FIG. 3.

The collagen solution was completely mixed with the MES buffer solution by repeated pumping between the first and 5 second syringes through the Tee so that flow through the narrow bore channels (for example between about 0.5 mm to about 0.25 mm) in the Tee piece strongly sheared the liquid. The pH was adjusted to 5.0 - 5.5. The collagen/buffer mixture was then mixed with the EDC and NHS solution (EDC:NHS at 1:1 10 molar equivalents ratio) at 0°C-4°C by directing the compositions through the manifold using another syringe.

Aliquots of each substantially homogeneous solution were immediately dispensed into onlay moulds and cured first at room temperature for 5 - 24 hours, such as 15 hours, and then 15 at 37°C for 15 - 24 hours, in 100% humidity environments at both temperatures.

Each final onlay sample was carefully separated from its mould after immersion in phosphate buffered saline (PBS) for 2 hours.

20 In some cases, these gels were immersed in an aqueous solution of a second reactive biopolymer to give further cross-linking and to add new biological factors.

Finally, the cross-linked onlay hydrogels were immersed 25 in PBS solution (0.5% in PBS, containing 1% chloroform) at 20°C to terminate any reactive residues and to extract out reaction byproducts. These sterile, equilibrium hydrated onlays were thoroughly rinsed in PBS before all testing.

For gels prepared from some collagen/EDC-NHS chemistries, at the higher collagen concentrations (10% and above), gels 30 were first soaked in pH 9.1 buffer to terminate any residual reactivity and give adequate extraction of reaction products before storage in chloroform-saturated PBS. This basic extraction removed epithelial toxicity problems for these samples. For many stoichiometries, soaking in chloroform

saturated PBS, followed by removal of chloroform residues gave sterile, non-cytotoxic gels.

Example 2

5 Ophthalmic devices with cell growth enhancer agents

Cell growth enhancer agents, such as the pentapeptide (YIGSR, the active unit in the laminin macromolecule) alone or in combination with synergistic peptides such as one containing, IKVAV, synergistic IGF, and substance P peptides that promote epithelial health, EGF, NGF, FGF or portions of these molecules can be incorporated into any of the collagen/EDC-NHS, cross-linked devices, including those with a second, EDC-NHS reactive bio-polymer. For YIGSR, the coupling 10 of this cell growth enhancer agent may be achieved via the reactivity of the free amine terminal group of a tyrosine residue on the agent. Extensive extraction after gellation 15 may be used to remove any unbound cell growth enhancer agent.

Specific formulation details of ophthalmic devices are 20 provided in Examples 3-13 and in Table 2, below.

Example 3

An ophthalmic device was made as described in Example 1 using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) with 25 N-hydroxysuccinimide (NHS) + collagens at pH 5.5 in MES buffer, at 0° - 4°C raised to 21°C for 15 h, then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

Example 4

30 An ophthalmic device was made as described in Example 1 using COP + EDC-NHS + collagens at pH 5.5 in MES buffer, at 0° - 4°C raised to 21°C for 15 h, then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio. [COP, copolymer, poly(N-isopropylacrylamide-co-acrylic acid) was prepared by free-

radical polymerization of NiPAAm and AAc in 1,4-dioxane with 2,2'-azobis-isobutyronitrile initiator under nitrogen at 70 °C].

5

Example 5

An ophthalmic device was made as described in Example 1 using EDC-NHS + chondroitin sulfate C (ChS) + collagens at pH 5.5 in MES buffer, at 0° - 4°C raised to 21°C for 15 h, then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

10

Example 6

An ophthalmic device was made as described in Example 1 using collagens + EDC-NHS + N,O-carboxymethylchitosan (CMC) at pH 5.5 in MES buffer, at 0° - 4°C, raised to 21°C for 15 h, 15 then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

Example 7

An ophthalmic device was made as described in Example 1 using collagens + EDC-NHS + N,O-carboxymethylchitosan (CMC) at 20 pH 5.5 in MES buffer, at 0° - 4°C, raised to 21°C for 2 h, then + second cross-linking when gel immersed in chitosan (1% aqueous solution, 5000 Da) in PBS for 4 h. Finally 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

25

Example 8

An ophthalmic device was made as described in Example 1 using collagens + EDC-NHS + hyaluronic acid (HA) and at pH 5.5 in MES buffer, at 0° - 4°C, raised to 21°C for 15 h, then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

30

Example 9

An ophthalmic device was made as described in Example 1 using collagens + EDC-NHS + Chondroitin sulfate (ChS) + hyaluronic acid (HA) at pH 5.5 in MES buffer, at 0° - 4°C,

raised to 21°C for 15 h, then raised to 37°C for 15 h. EDC:NHS = 1:1 molar equivalents ratio.

Example 10

5 An ophthalmic device was made as described in Example 1 using collagens + hyaluronic acid aldehyde (HA-CHO) + sodium cyanoborohydride at pH 7 - 8 in PBS at 0° - 4°C, raised to 21°C for 15 h, then 15 h at 37°C. HA-CHO was prepared from HA (0.1 g) by oxidative cleavage with sodium periodate (0.05 g) 10 for 2 h at 21°C. The aqueous solution was dialysed against water for 2 days.

Example 11

15 An ophthalmic device was made as described in Example 1 using collagens + EDC-NHS + alginate at pH 5.5 in MES buffer, at 0° - 4°C, raised to 21°C for 15 h, then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

Example 12

20 An ophthalmic device was made as described in Example 1 using glutaraldehyde ("Glut", diluted to 1% in water) + collagens at pH 5.5 in MES buffer at 0° - 4°C raised to 21°C for 2 h, then + second cross-linking when gel immersed in chitosan (1% aqueous solution, 5000 Da) in PBS for 4 h. Gels 25 in their moulds were raised to 37°C for 15 h before removal under PBS.

Example 13

30 An ophthalmic device was made as described in Example 1 using collagens + EDC-NHS + chitosan at pH 5.5 in MES buffer, at 0° - 4°C, raised to 21°C for 15 h, then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

Example 14

An ophthalmic device was made as described in Example 1 using EDC-NHS + chondroitin sulfate C (ChS) + collagens at pH 7-8 in PBS buffer, at 0° - 4°C raised to 21°C for 15 h, then 15 h at 37°C. EDC:NHS = 1:1 molar equivalents ratio.

5 All devices of Examples 3-14 gave robust, clear and flexible gels with all of the commercial collagens and reactant ratios indicated in Table 2, below.

10 Some hydrogels for onlay applications were characterized by DSC, optical clarity and refractive index, measurements, tensile properties (stiffness, maximum tensile strength, elongation at break, Table 2) and in vivo performance. From 15 DSC measurements on gels after reaction for all examples, an increase in the denaturing temperature and a decrease in $\Delta H_{\text{denature}}$ were found, consistent with cross-linking of the collagen. Refractive indices of all formulations in Table 2 were in the 1.341 to 1.349 range.

Example 15

In vitro onlay performance (Table 2)

20

The methods disclosed by Li et al. PNAS 100:15346-15351 (2003) were used to evaluate how epithelial cells (human, immortalized corneal epi. cells, HCEC) grow to confluence over hydrogels (days to confluence), to evaluate how HCEC cells 25 stratify over hydrogels, and to evaluate chick dorsal root ganglion nerve growth over and into hydrogels (latter reported as micron/day growth where data available).

Human corneas restore their epithelium in 3 - 5 days after complete removal.

30 In vitro test duration was usually about 6 -8 days, but the better formulations allowed re-epithelialisation to confluence within 3 - 5 days or less. For denser gels (>5% collagen), extensive nerve over growth (300 micron extension) was found in the in vitro tests for many formulations. Nerve

in-growth slows rapidly as gel stiffness increases, but was seen by in-depth microscopy.

Table 2. Composition and performance of hydrogels[†]

Example #	Collagen supplier, (Table 1) (initial concn. wt/vol %)	Collagen/XL Equiv. Ratio or (wt/wt)	Final collagen concentration in the gel (w/v %)	Maximum stress, g force*	Strain at break, mm*	Stiffness, g/mm*	In vitro Epi. cells, days to confluence	In vitro Nerve growth in 6 days**
2	B AFDP: (dissolved at 10%)	Col-NH ₂ :EDC=5:1 Col:YIGSR = 5:0.0001	7.2				3-5	Over: fast. In: 27 μ m/d
3	A, (10% bovine)	Col-NH ₂ :EDC = 5:1	7.3	8.0	2.6	4.0		
3	B, AFDP: (dissolved at 10%)	Col-NH ₂ :EDC = 5:1	7.3	9.7	4.0	4.4	2-3	Over: fast In: 40 μ m/d
3	B, AFDP: (dissolved at 15%)	Col-NH ₂ :EDC = 5:1	10.8	13.08	4.6	3.0	2-3	
3	B, AFDP: (dissolved at 20%) 350 μ m thickness gel	Col-NH ₂ :EDC = 10:1	14.3	11.95	4.3	3.0	2-3	
3	B, (AFDP, dissolved at 32%)	Col-NH ₂ :EDC = 1:1	18.0	14			2-3	Over : fast In: = 30 μ m/d
3	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 1:1	2.7	3.1	2.0	1.7	3-5	Over : fast
5	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:ChS= (9:1)	2.7	2.5	1.8	1.4	3	Over : fast In: = 41 μ m/d
5	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:ChS= (4:1)	2.7	2.7	1.8	1.5	3	Over : fast In: = 73 μ m/d
5	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:ChS= (3:1)	2.7	3.1	1.5	1.5	3	Over In: = 70 μ m/d

[†]Abbreviations: Col collagen; Glut glutaraldehyde; HA hyaluronic acid; ChS

chondroitin sulfate C; Col-NH₂ free amine content of collagen; AFDP

acid, freeze dried porcine; epi. epithelial; ND not determined.

*500 μ m thick, 12 mm diameter implants unless otherwise indicated. Stress, strain and stiffness data from the suture pull out method as disclosed by Li et al. PNAS 100:15346-15351 (2003).

**Over: neurites from DRG overgrew hydrogel. In: neurites grew into the hydrogel to the indicated length in 6 days.

Table 2 (cont.)

Example #	Collagen supplier, (Initial concn. Wt/vol %)	Collagen/XL Equiv. Ratio or (wt/wt)	Final collagen concentration in the gel (w/v %)	Maximum stress, g force*	Strain at break(m m)*	Stiffness, g/mm*	In vitro Epi. growth, days to confluence	In vitro Nerve growth in 6 days**
6	A, (3.5% neutral bovine)	Col-NH ₂ :EDC =1:1 Col:CMC = (1:0.5)		3.6	1.6	2.0		
6	B, (AFDP, dissolved at 32%)	Col-NH ₂ :EDC = 1:1.3 Col:CMC = (15:1)	14.5	6.0			3	
7	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 1:1 Col:CMC = (2:1) + soluble chitosan		2.9	1.6	1.9		
8	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:HA= (9:1)	2.2	2.5	2.2	1.08	3-5	
8	A, (5% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:HA= (4:1)	2.2	2.4	2.2	2.07	3-5	
8	A, (10% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:HA= (3:1)	2.2	2.0	1.8	1.13	3-5	
9	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 0.5:1.0 Col:HA:ChS=9:1:1	2.3	3.0	1.7	1.7	3-5	Over and in growth
10	A, (3.5% neutral bovine) 350 μ m thickness gel	Col-NH ₂ : HA-CHO = 1:1	3.2	1.0		0.7		
11	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:Alg = 4:1	2.7	3.0	2.0	1.6	3-5	Over : fast In: = 41 μ m/d
11	A, (3.5% neutral bovine)	Col-NH ₂ :EDC = 2:1 Col:Alg = 2:1	2.7	3.4	2.5	1.5	3-5	Over: fast In: = 13 μ m/d
12	A, (3.5% neutral bovine)	Col:Glut= (130:1)?? + soluble chitosan		3.1	2.1	1.5		

Example #	Collagen supplier, (Initial concn. Wt/vol %)	Collagen/XL Equiv. Ratio or (wt/wt)	Final collagen concentration in the gel (w/v %)	Maximum stress, g force*	Strain at break(mm)*	Stiffness, g/mm*	In vitro Epi. growth, days to confluence	In vitro Nerve growth in 6 days**
13	B, (11% AFDP), 900 μ m thickness gel	Col-NH ₂ :EDC = 0.33:1.0 Col:chitosan =(15:1)	5.8	8.32	3.29	2.57	4	
13	B, (11% AFDP), 500 μ m thickness gel	Col-NH ₂ :EDC = 0.66:1.0 Col:chitosan =(15:1)	5.8	4.25	4.02	1.32		
13	B, (11% AFDP), 900 μ m thickness gel	Col-NH ₂ :EDC = 0.66:1.0 Col:chitosan =(15:1)	5.8	8.46	5.23	2.17		

[†]Abbreviations: Col collagen; Glut glutaraldehyde; HA hyaluronic acid; Chs chondroitin sulfate C; Col-NH₂ free amine content of collagen; AFDP acid, freeze dried porcine; epi. epithelial; ND not determined.

*500 μ m thick, 12 mm diameter implants unless otherwise indicated. Stress, strain and stiffness data from the suture pull out method as disclosed by Li et al. PNAS 100:15346-15351 (2003).

**Over: neurites from DRG overgrew hydrogel. In: neurites grew into the hydrogel to the indicated length in 6 days.

10

EXAMPLE 16

In vivo onlay performance

Onlays were prepared as described in Example 1. A first set of onlays were prepared from 10% (w/v) porcine collagen with EDC/NHS. A second set of onlays were prepared from 3.5% (w/v) bovine collagen with chondroitin sulphate (CSC) and EDC/NHS. The onlays had a diameter of about 6 mm, a center thickness of about 70 μ m, and 30 μ m sloped edges.

To implant the onlays, the epithelium of a pig was treated with 45% ethanol for 30-45 seconds. A butterfly incision was made and a pocket was formed in the epithelium. The onlays were stained with blue non-cytotoxic dye (Gel-CodeTM) for visualization. The pre-stained onlays were

inserted into the pocket. A protective contact lens was sutured over the eye.

Visual inspection was performed to evaluate inflammation, redness, and/or vascular invasion of the cornea. Slit lamp 5 examinations were used to assess corneal clarity. A tonopen was used to measure intraocular pressure. A Cochet-Bonnet aesthesiometer was used to determine touch sensitivity of the cornea. The touch sensitivity may be useful to evaluate the presence of functional nerves, which was corroborated with in 10 vivo confocal imaging and immunohistochemistry of the harvested corneas with implants. Corneal topography was examined with a PAR Corneal Topography System (CTS) immediately before implantation and three weeks after surgery.

Corneal topography was performed by aligning an eye of an 15 anesthetized pig with the CTS. A dilute solution of fluorescein and artificial tears was applied to the eye to coat the corneal surface and enable visualization of a target grid. The instrument focal plane was adjusted to bring the target grid into focus on the anterior corneal surface. A 20 digital image of the grid was captured. The digital image was analyzed to provide a measure of the shape of the anterior corneal surface. Comparing the digital image before and after the implantation of the onlay can be used to evaluate changes in the shape of the cornea due to the placement of the onlay.

25 In vivo confocal microscopy permits images of different depths of the cornea in live pigs to be captured, and thus allows the response of the eye to the ophthalmic device to be monitored. For example, the confocal microscopy can be used to monitor the presence of nerves in the device. In vivo 30 confocal microscopy was performed by examining anesthetized pigs with a Nidek Confoscan 3 in vivo confocal microscope before implantation of the ophthalmic device and 3 weeks after the surgery. Artificial tears were placed on the eye to be examined. Two drops of a local anesthetic were applied to the

eye to reduce eyeball movement. The confocal lens (gel immersion) was brought into contact with the cornea with a layer of gel on the front surface of the lens for refractive index matching. The instrument focal plane was adjusted to 5 bring the corneal endothelium into focus, and then images of the cornea were taken as the focal plane of the lens was scanned through a depth equal to the thickness of the cornea.

10 Immunohistochemistry was used in addition to histopathological examination of hematoxylin and eosin (H&E) stained tissue sections to determine if corneal epithelial recovery over the onlay and early indication of adhesion and interaction with the underlying onlays. Immunohistochemistry was also used to establish the presence or absence of nerves and any infiltration of immune and inflammatory cells. Anti- 15 neurofilament staining was performed on half corneas, with and without implanted onlays after permeabilization with detergent, using conventional techniques. Immunofluorescence was used to visualize bound antibody.

20 Corneas that received a corneal onlay, as discussed above, healed well and remained optically clear with minimal or no redness or inflammation. There were no signs of vascular infiltration. Normal intraocular pressures were observed. The post-operative corneas exhibited touch 25 sensitivity. Topograph measurements indicated that the implanted onlays were able to effect changes in corneal topography. The onlays resulted in a change of about 50 μm in thickness in central corneal elevation. The epithelium adhered well to the onlays. In vivo corneal microscopy 30 revealed good general corneal structure with subepithelial and stromal nerves, and cells from the epithelium through to the endothelium. H&E stained cryo-sections showed integration of the onlays into the host cornea. Immunohistochemistry demonstrated little, if any, change in the adhesivity of the cells in onlay-implanted corneas compared to untreated corneas

using a stain for E-cadherin. Staining for Keratin 3 and E-cadherin was comparable to controls. Collagen type VII staining for anchoring fibers with the basement membrane complex showed less distinct staining than controls. Staining 5 for α 6 integrin showed localization in the basal epithelial cells in both operated and untreated controls. Anti-neurofilament 200 antibody staining showed the presence of nerves in the implantation site in corneas with onlays. Anti CD 45 antibody staining revealed no inflammatory or immune 10 reaction.

EXAMPLE 17

Ablation of corneal onlays

15 Collagen/EDC and collagen/chitosan onlays were ablated using a VISX Star S4 excimer laser (Table 3). Surface topography measurements of the onlays were obtained before and after treatment with a PAR Corneal Topography System (CTS). For the treatment, the onlays were removed from the storage 20 solution and laid on a spherical surface made of PMMA.

Phototherapeutic keratectomy (PTK) surgery delivers a uniform number of laser pulses (or energy) to an entire ablation zone. Photorefractive keratectomy (PRK) surgery varies pulse density over the ablation zone to achieve a 25 desired change in curvature. AZD refers to ablation zone diameter. Depth is the predicted depth of the treatment on a human cornea as reported by the laser manufacturer.

TABLE 3: Ablation Parameters.

Surgery	Type	AZD (mm)	Sphere (D)		Depth (μm)
			Sph (D)	Cyl (D)	
1	PTK	5	----	----	10
2	PTK	5	----	----	20
3	PRK	6	2 +2	0	26
4	PRK	6	-	0	19
5	PRK	6	4 +4	0	51
6	PRK	6	-	0	38
7	PRK	6	4 -+2	-	30

Difference maps were generated from the pre- and post-operation topographies of the collagen/EDC onlays to display
5 the effects of the ablation.

The PTK ablations were expected to produce a fairly constant central blue region ~5 mm in diameter (for the difference map). A small gradient in the amount of tissue removed was expected since the onlay is a curved surface.
10 Myopic sphere PRK ablations were expected to remove the maximum tissue depth centrally. The depth of tissue removed was expected to gradually decrease to zero at the edge of the ablation. Hyperopic sphere corrections were expected to leave the central 1 mm diameter untouched and remove tissue
15 maximally at the edge of the treatment zone, a transition zone was also expected to be created peripherally out to 9 mm from the center. Difference maps after a hyperopic correction were expected to display a ring of blue around a central green zone. The difference map from the myopic astigmatic
20 correction was expected to appear similar to the map from myopic spherical correction except its blue pattern was expected to be elliptical.

The difference maps from the ablated onlays demonstrated the aforementioned expected tissue removal patterns in all the

difference maps. The maximum depth of tissue removed appeared to be greater than that predicted for the human cornea. For example, the rate at which the corneal onlay material was removed was between about 1.7 and about 2 times the rate of 5 corneal removal. The difference between the ablation rate of the onlay material and a cornea was not uniform across the samples. The rate differences may be due to, among other things, the depth of treatment measurement, material densities and surface roughness, and water content of the material.

10 The collagen/chitosan onlays were observed to ablate at a faster rate than the collagen/EDC onlays. The difference could be due to hydration issues. For example, the post-operative collagen/chitosan onlays may have had a lower water content than the collagen/EDC onlays.

15 The ophthalmic device may also comprise a strength increasing component, such as urethane.

EXAMPLE 18

Human recombinant collagen ophthalmic devices

20 Cross-linked collagen hydrogels were prepared by mixing 0.3 ml of 13.7 wt% human recombinant type I collagen obtained from FibroGen (San Francisco, CA) and 0.3 ml of 0.625 M morpholinoethanesulfonic acid (MES) using a syringe based 25 system as described herein. The mixing occurred at a reduced temperature by performing the mixing in an ice-water bath.

After a homogenous solution was obtained, 57 μ l of EDC/NHS was injected into the mixture in a molar equivalent ratio to collagen free amine (coll-NH₂) groups of 3:3:1. To 30 adjust the pH of the solution to about 5, NaOH (2N) was added to the mixture.

The mixture was cast into glass or plastic molds and left at room temperature with 100% humidity for 16 hours. The

molds were subsequently transferred into an incubator for post-curing at 37°C for 5 hours.

Other hydrogels with human recombinant collagen type I with ratios of EDC/NHS to collagen coll-NH₂ groups of 1:1:1 and 5 6:6:1 were also prepared using this method.

Refractive index (RI) was determined on a VEE GEE refractometer. Optical transmission was measured at wavelengths of white light, 450 nm, 500 nm, 550 nm, 600 nm, and 650 nm. Direct tensile property measurements, such as 10 stress, break strain, and moduli, were determined on an Instron electromechanical tester (Model 3340). The size of the samples were 5 mm x 5 mm x 0.5 mm. The water content of the hydrogels were calculated according the following equation:

$$15 \quad (W - W_0) / W\% \quad \text{where } W_0 \text{ and } W \text{ denote weights of dried and swollen samples, respectively.}$$

where W_0 and W denote weights of dried and swollen samples, respectively.

A human recombinant collagen hydrogel with a ratio of EDC/NHS/Coll-NH₂ of 1/1/1 (molar equivalents) (designated F1) 20 had a refractive index of 1.3457±0.0013. A human recombinant collagen hydrogel with a ratio of EDC/NHS/Coll-NH₂ of 3/3/1 (molar equivalents) (designated F3) had a refractive index of 1.3451±0.0002. A human recombinant collagen hydrogel with a ratio of EDC/NHS/Coll-NH₂ of 6/6/1 (molar equivalents) 25 (designated F6) had a refractive index of 1.3465±0.0001.

Table 4 summarizes the optical transmission of the different hydrogels.

TABLE 4. Optical Transmission

Wavelength(nm)	White	450	500	550	600	650
		Average Transmission (%)				
F1	86.7±0.9	69.7±1.2	76.0±1.3	79.2±1.4	82.4±1.3	84.9±1.4
F3	90.7±2.5	85.8±3.5	86.4±2.9	86.7±2.6	88.0±2.4	89.6±2.6
F6	75.5±1.5	48.7±0.4	57.7±1.1	62.7±1.1	67.6±1.4	71.6±1.7

The hydrogel material designated F3 appeared to show the most acceptable optical properties. Visually, or macroscopically, F3 appeared to have the greatest transparency compared to the other human recombinant hydrogels.

5 Table 5 provides mechanical properties of the present human recombinant hydrogels.

TABLE 5. Mechanical Properties

Samples	F1	F3	F6
Average Maximum Stress(KPa)	62.6± 9.9	117.2±36.9	149.9±57.7
Average Break Stress(KPa)	67.1± 21.0	110.5±49.7	99.5±60.8
Average Break Strain(%)	62.60± 6.82	50.20±7.55	23.51±9.03
Average Modulus(MPa)	0.281± 0.032	0.525±0.124	1.949±0.939

10 The hydrogel F3 appears to have a relatively low modulus, but acceptable other mechanical properties.

Table 6 provides water content values for the hydrogel materials.

15 TABLE 6. Equilibrated Water Contents

Samples	F1	F3	F6
Water content (%)	92.82±0.68	92.63±0.61	91.40±0.38

It is clear that the hydrogels are highly hydrated.

20 In the present example, a pH indicator was added to the MES buffer to help monitor pH changes. The particular indicator used in this example is Alizarin Red S (Sigma Aldrich).

FIG. 4 is a graph of human corneal epithelial cell growth 25 on the human recombinant collagen sample F1 over a 7 day period. FIG. 5 is a graph of human corneal epithelial cell

growth on the human recombinant collagen sample F3 over a 7 day period. FIG. 6 is a graph of human corneal epithelial cell growth on the human recombinant collagen sample F6 over a 7 day period.

5 The cell growth observed on the recombinant hydrogel materials was greater than that observed for the control experiments.

FIG. 7 is a photograph demonstrating that the hydrogel material F3 persisted in vivo for at least 30 days.

10

EXAMPLE 19

Collagen-poly(NIPAAm-co-AAC) compositions

15 A composition was prepared using the EDC/NHS cross-linking methods described herein (Example 4). The starting collagen concentrations was 15%. The final collagen concentration was 11%. The final poly(NIPAAm-co-Aac) concentration was 3%. The total solid concentration in the gel was 14%.

20 This material had a refractive index of 1.3542, a tensile strength of 11g-force, an elongation of 3.3 mm, and a modulus of 3.8 g-force/mm from the suture pull out method as disclosed by Li et al. PNAS 100:15346-15351 (2003).

25 The denature temperature increased from 40°C before crosslinking to 50°C after crosslinking. The material had a higher optical transmission and lower back scatter than human cornea or rabbit cornea. For example, with white light, the percent transmission was about 102% for the hydrogel material, and about 93% for the human cornea, and 78% for the rabbit cornea. The hydrogel had percent transmissions of about 90%, 96%, 100%, 101%, and 103% for wavelengths of light of 450 nm, 30 500 nm, 550 nm, 600 nm, and 650 nm, respectively. The human cornea and the rabbit cornea exhibited percent transmissions less than 100% at all tested wavelengths, and exhibited

percent transmission that were consistently lower than the hydrogel material at each wavelength.

The hydrogel material demonstrated corneal epithelial cell confluence at seven days after seeding.

5

EXAMPLE 20

Collagen/chondroitin sulfate compositions

Biosynthetic matrices with high optical clarity and tensile strength were developed using collagen I, with chondroitin sulphate (CSC) as a proteoglycan equivalent. Hydrogels with up to 30% (wt/wt) CSC to collagen dry weight were prepared under controlled conditions, without coagulation or collagen fibrillogenesis which can cause loss of optical clarity. The hydrogels were characterized physically and biochemically. The in vitro test showed that human corneal epithelial cells (HCECs) grew well on gels' surfaces and stratified successfully. The matrix supported good nerve in growth. Similar results were also obtained in vivo.

Compositions were prepared similar to Example 14 described herein. CSC was covalently bound to collagen using EDC and NHS chemistry.

Collagen (3.5 w/v%) and CSC gels with different CSC to collagen dry weight ratios and different EDC to collagen-NH₂ mole equivalent ratios were prepared by using EDC/NHS (1:1 mole equivalent) cross-linking techniques, as discussed herein. All gels were visually transparent. The compositions had higher light transmission and low light scatter compared to human cornea (about 87% transmission and 3% back scatter), as shown in Table 7.

TABLE 7-Transmission and Light Scatter

CSC to collagen weight ratio (%)	0	5	10	20	30
Transmission (%)	89.9	95.5	93.0	90.5	97.3
Back Scatter (%)	0.30	0.19	0.19	0.17	0.19
EDC to NH ₂ ratio	0.25	0.5	1.0		2.0
Transmission (%)	96.7	100	99.9		88.2
Back Scatter (%)	0.24	0.28	0.16		0.20

Refractive indices were between 1.34-1.35, which is close to refractive index of the human cornea (1.376).

5 The swelling ratio of the gels made by using different EDC to collagen-NH₂ mole ratios were measured and calculated by the following equation:

$$\text{Swelling ratio} = (W_w - W_d) / W_d$$

10 where W_w is the weight of the hydrated gel and W_d is the weight of dry gel.

15 Collagen-CSC crosslinking using EDC/NHS results in the formation of crosslinks between carboxylic acid and amine groups. The results (FIG. 9) suggested that increasing EDC to collagen-NH₂ ratios decreased the swelling ratio of the collagen-CSC gel because it introduced more condensed networks.

20 Mechanical properties measurement of the implants were performed by the suture pull out method as disclosed by Li et al. PNAS 100:15346-15351 (2003). The implants were fully hydrated in PBS and drawn at a speed of 10mm/min. The tensile strength was monitored at rupture of the implant (500μm in thickness and 12mm in diameter). Tensile strength of the gels was enhanced by increasing the EDC to NH₂ mole ratio (FIG. 10). However, the material became brittle when the amount of EDC was increased substantially, thus the tensile strength decreased a little when the EDC to collagen-NH₂ mole ratio was 2 or higher.

The tensile strength of the gel can also be enhanced by increased concentration of collagen, as shown in FIG. 11 (cf. use 10% collagen instead of 3.5%). The tensile strength was increased from 2.65 to 10.02 gram-force and the swelling ratio 5 decreased from 21.5 to 12.1.

The efficiency of the crosslinking was evaluated by differential scanning calorimetry (DSC). Heating collagen or crosslinked collagen hydrogels will induce a structural transition of the native triple helical structure at a 10 temperature depending on the nature and the degree of the crosslinking. Collagen solution and crosslinked fully hydrated, collagen hydrogels were characterized in a hermetically sealed pan and temperature of the samples was raised at a constant rate of 2°C/min. The temperature at the 15 maximal peak was recorded as the denature temperature. As the EDC to NH₂ ratio was increased, the denature temperature increased from 42.4°C to 56.6°C (FIG.12A), which suggested that introduction of covalent crosslinks increased the stability of the triple helix, and thus increased denature 20 temperature. The denature temperature of the collagen-CSC gel was higher than the collagen only gel (FIG.12B). However, changing the CSC to collagen mole ratio in collagen-CSC gels did not affect the denature temperature.

In vitro growth of human corneal epithelial cells from an 25 established cell line was observed. Nerve growth was performed in vitro, using dorsal root ganglia implanted into the gel. Neurites were grown for 7 days, the gels were stained for neurofilament and neurite extension was measured. Neurites grew well in all collagen-CSC gels (FIG. 13).

30 Increasing the concentration of CSC from 5% to 20% greatly enhanced the length of neurite extension within the gels. No additional benefit was apparent in gels containing 30% CSC (Fig. 13). Excellent epithelial coverage and implant integration were observed.

Example 21

Type III Collagen Compositions

5 **Materials.** Human recombinant type III collagen (5.1% w/w FibroGen Inc), 0.625 M morpholinoethanesulfonic acid [MES, containing Aalizarin Red S pH indicator(6.5 mg/100ml water)], 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide HCl (EDC), N-hydroxy-succinimide(NHS).

10 Hydrogels were made from 18.3% (w/w) type III collagen solution. 0.3 ml of 18.2 wt% human recombinant type III collagen (concentrated from 5.1% w/w human recombinant type III collagen FibroGen Inc) and 0.3 ml of MES(0.625 M) were mixed in two bubble free syringes connected with a plastic Tee 15 in ice-water bath. After a homogenous solution was formed, 33.5mg of EDC and 20.1 mg of NHS were dissolved in 0.125 ml of MES, of which 57 μ l was taken and injected into the above syringes in molar ratio of EDC:NHS:collagen-NH₂ of 3:3:1. No NaOH solution was added since the mixture appeared pink, 20 indicating pH around 5. The mixture was mixed thoroughly and cast into glass moulds (thickness 434 μ m) and left at room temperature, at 100% humidity, for 16 h. Then the moulds were transferred into an incubator for post-curing at 37 °C for 5 h. The resulting flat hydrogels were removed and soaked in 10 mM 25 PBS with fresh buffer being replaced at 8 h intervals. The hydrogels obtained were immersed in 10 mM PBS containing 1% chloroform and stored in 4 °C refrigerator.

Addtional type III collagen hydrogels with ratios of EDC:NHS:collagen-NH₂ of 2:2:1 and 1:1:1 were also prepared 30 using the above-described method. All the gels obtained were transparent.

Hydrogels were also made from 5.1%(w/w) type III collagen solution. 0.3 ml of 5.1 wt% human recombinant type III

collagen and 50 μ l of MES (0.625 M) were mixed in two bubble free syringes connected with a plastic Tee in ice-water bath. After a homogenous solution was formed, 9.3mg of EDC and 5.6 mg of NHS were dissolved in 0.125 ml of MES, of which 57 μ l was taken and injected into the above syringes in molar ratio of EDC:NHS: collagen-NH₂ of 3:3:1. No NaOH solution was added since the mixture appeared pink, indicating pH around 5. The mixture was mixed thoroughly and cast into glass moulds (thickness 434 μ m) and left at room temperature with 100% humidity for 16 h. Then the moulds were transferred into an incubator for post-curing at 37 °C for 5 h. The resulting flat hydrogels were taken out and soaked in 10 mM PBS with fresh buffer being replaced at 8 h intervals. Lastly the hydrogels obtained were immersed in 10 mM PBS containing 1% chloroform and stored in 4 °C refrigerator. The resultant gel was optically clear.

The final collagen contents for 18.3% w/w collagen starting concentration was 8.36 % (w/v) (calculated based on the dilution factors after added every components) or approximately 10% (w/v) (measured).

The final collagen contents for 5.1% w/w collagen starting concentration was 3.76 % (w/v) (calculated based on the dilution factors after added every components) or approximately 4% (w/v) (measured).

25

While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and other embodiments are within the scope of the invention.

30

A number of publications, patents, and patent applications have been cited hereinabove. Each of the cited publications, patents, and patent applications are hereby incorporated by reference in their entireties.

What is claimed is:

1. An optically clear biosynthetic composition comprising cross-linked collagen, wherein the composition comprises an amount of collagen between about 5% and about 50% by weight or volume.
2. The composition of claim 1, wherein the amount of collagen is at least 6% by weight or volume.
3. The composition of claim 2, wherein the amount of collagen is at least 10% by weight or volume.
4. The composition of claim 3, wherein the amount of collagen is between about 10% and about 30% by weight or volume.
5. The composition of claim 4, wherein the amount of collagen is between about 10% and about 24% by weight or volume.
6. The composition of claim 1, wherein the cross-linked collagen comprises one type of collagen.
7. The composition of claim 1, wherein the cross-linked collagen comprises two or more types of collagen.
8. The composition of claim 1, which further comprises a cell growth enhancer agent.
9. The composition of claim 8, wherein the cell growth enhancer agent is a peptide.
10. The composition of claim 9, wherein the peptide has an amino acid sequence of RGD, YIGSR, or IKVAV.
11. The composition of claim 8, wherein the cell growth enhancer agent is selected from the group consisting of neurotrophic factors, nerve growth factors, and epidermal growth factors.
12. The composition of claim 11, wherein the cell growth enhancer agent is distributed substantially throughout the composition.

13. The composition of claim 1, wherein the collagen is the sole water-swellable polymer of the device.

14. The composition of claim 1, wherein collagen was cross-linked at an acidic pH.

15. The device of claim 14, wherein the acidic pH is between about 5.0 and about 5.5.

16. The composition of claim 1, wherein the cross-linked collagen comprises atelocollagen, type I collagen, type III collagen, or a combination thereof.

17. The composition of claim 1, wherein the cross-linked collagen comprises recombinant collagen.

18. The composition of claim 1, wherein the cross-linked collagen comprises collagen isolated from an animal.

19. The composition of any one of claims 1 - 18, wherein the cross-linked collagen is produced by a process of cross-linking collagen polymers using a cross-linker other than glutaraldehyde.

20. The composition of claim 19, wherein the cross-linked collagen is produced by a process of cross-linking collagen polymers using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide.

21. The composition of claim 1, which further comprises poly(N-isopropylacrylamide-co-acrylic acid), chondroitin sulfate, N,O-carboxymethylchitosan, hyaluronic acid, hyaluronic acid aldehyde or alginate.

22. The composition of any one of claims 1 - 21 which is effective in facilitating nerve growth on and/or into the composition.

23. A method of making a composition according to any one of claim 1 - 22, comprising:

combining collagen polymers with a cross-linker agent at an acidic pH; and

curing the resultant combination to form the composition comprising cross-linked collagen.

24. The method of claim 23, wherein the combining step comprises mixing the collagen polymers and the cross-linker agent in a system configured to produce high shear forces on the resultant combination.

25. The method of claim 23, wherein the combining occurs at a temperature between about 0°C and about 5°C.

26. The method of claim 27, further comprising adding a cell growth enhancer agent to the combination.

27. A method of treating an ophthalmic disease, disorder, or injury comprising:

contacting an eye of a subject having said ophthalmic disease, disorder or injury with an ophthalmic device manufactured from a composition according to any one of claims 1 - 23.

28. Use of the composition according to any one of claims 1 - 23 to manufacture an ophthalmic device for treating an ophthalmic disease, disorder or injury in a subject in need thereof.

29. Use of the composition according to any one of claims 1 - 23 for treating an ophthalmic disease, disorder or injury in a subject in need thereof.




Fig.1.




Fig.2




Fig.3






FIG. 8








FIG. 8A






FIG. 9






FIG. 10






FIG. 13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/001240

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons :

1. Claim Nos. : 27
because they relate to subject matter not required to be searched by this Authority, namely :
claim 27 is directed to a method of treatment of the human or animal body (Rule 39.1 (iv) PCT), however, the search was carried out on the alleged effects of the composition.
2. Claim Nos. :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically :
3. Claim Nos. :
because they are dependant claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows :

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos. :
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos. :

Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/001240

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC(7): A61L 27/24, A61L 27/54, A61F 2/14, G02B 1/00</p> <p>According to International Patent Classification (IPC) or to both national classification and IPC</p>																									
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) IPC(7): A61L-27, G02B-1, A61F-2/14</p>																									
<p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p>																									
<p>Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used) Canadian Patent Database, WEST (USPTO), PubMed Keywords = collagen; cross*link*; corneal, eye, ophthalm*; clear, transparent and translucent</p>																									
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>US 4,581,030 (Bruns, R. B. et al.) 8 April 1986 (08.04.1986) Abstract, Col. 2-3 and Examples 1 and 2</td> <td>1-7, 13, 16, 18, 19, 23 and 27-29</td> </tr> <tr> <td>Y</td> <td></td> <td>8-12, 17, 21, 22 and 26</td> </tr> <tr> <td>X</td> <td>US 4,223,984 (Miyata, T. et al.) 23 September 1980 (23.09.1980) Entire document</td> <td>1-7, 13-16, 18, 19, 23, and 27-29</td> </tr> <tr> <td>Y</td> <td></td> <td>8-12, 17, 21, 22 and 26</td> </tr> <tr> <td>X</td> <td>US 2003/0018123 (Bagrov, S. N. et al.) 23 January 2003 (23.01.2003) Entire document</td> <td>1-6, 16, 19, 23 and 27-29</td> </tr> <tr> <td>Y</td> <td></td> <td>8-12, 17, 21, 22 and 26</td> </tr> <tr> <td>Y</td> <td>Li, F. et al. "Cellular and nerve regeneration within a bioprosthetic extracellular matrix for corneal implantation" Proc. Nat. Acad. Sci. 2003 (Dec. 23), Vol. 100 (No. 26), pages 15346-15351. Entire document</td> <td>8-12, 17, 21, 22 and 26</td> </tr> </tbody> </table>		Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	US 4,581,030 (Bruns, R. B. et al.) 8 April 1986 (08.04.1986) Abstract, Col. 2-3 and Examples 1 and 2	1-7, 13, 16, 18, 19, 23 and 27-29	Y		8-12, 17, 21, 22 and 26	X	US 4,223,984 (Miyata, T. et al.) 23 September 1980 (23.09.1980) Entire document	1-7, 13-16, 18, 19, 23, and 27-29	Y		8-12, 17, 21, 22 and 26	X	US 2003/0018123 (Bagrov, S. N. et al.) 23 January 2003 (23.01.2003) Entire document	1-6, 16, 19, 23 and 27-29	Y		8-12, 17, 21, 22 and 26	Y	Li, F. et al. "Cellular and nerve regeneration within a bioprosthetic extracellular matrix for corneal implantation" Proc. Nat. Acad. Sci. 2003 (Dec. 23), Vol. 100 (No. 26), pages 15346-15351. Entire document	8-12, 17, 21, 22 and 26
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																							
X	US 4,581,030 (Bruns, R. B. et al.) 8 April 1986 (08.04.1986) Abstract, Col. 2-3 and Examples 1 and 2	1-7, 13, 16, 18, 19, 23 and 27-29																							
Y		8-12, 17, 21, 22 and 26																							
X	US 4,223,984 (Miyata, T. et al.) 23 September 1980 (23.09.1980) Entire document	1-7, 13-16, 18, 19, 23, and 27-29																							
Y		8-12, 17, 21, 22 and 26																							
X	US 2003/0018123 (Bagrov, S. N. et al.) 23 January 2003 (23.01.2003) Entire document	1-6, 16, 19, 23 and 27-29																							
Y		8-12, 17, 21, 22 and 26																							
Y	Li, F. et al. "Cellular and nerve regeneration within a bioprosthetic extracellular matrix for corneal implantation" Proc. Nat. Acad. Sci. 2003 (Dec. 23), Vol. 100 (No. 26), pages 15346-15351. Entire document	8-12, 17, 21, 22 and 26																							
<p><input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.</p>																									
<p>* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed</p>																									
<p><input checked="" type="checkbox"/> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p><input checked="" type="checkbox"/> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p><input checked="" type="checkbox"/> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p><input checked="" type="checkbox"/> document member of the same patent family</p>																									
<p>Date of the actual completion of the international search 24 November 2005 (24-11-2005)</p>																									
<p>Date of mailing of the international search report 7 December 2005 (07-12-2005)</p>																									
<p>Name and mailing address of the ISA/CA Canadian Intellectual Property Office Place du Portage I, C114 - 1st Floor, Box PCT 50 Victoria Street Gatineau, Quebec K1A 0C9 Facsimile No.: 001(819)953-2476</p>																									

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/001240

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	Li, F. et al. "Recruitment of multiple cell lines by collagen-synthetic copolymer matrices in corneal regeneration" <i>Biomaterials</i> 2005 (Jun.), Vol. 26 (No. 16), pages 3093-3104. Entire document	8-12, 17, 21, 22 and 26
Y	Carlsson, D. J. et al. "Bioengineered corneas: how close are we?" <i>Curr. Opin. Ophthalmol.</i> 2003 (Aug.), Vol. 14 (No. 4), pages 192-197. Pages 195-196	20
A	Leskul, M. et al. "CxGELSIX: a novel preparation of type VI collagen with possible use as a biomaterial" <i>Cornea</i> 2000 (Mar.), Vol. 19 (No. 2), pages 194-203.	1-29
A	Doillon, C. J. et al. "A collagen-based scaffold for a tissue engineered human cornea: physical and physiological properties" <i>Int. J. Artif. Organs</i> 2003 (Aug.), Vol. 26 (No. 8), pages 764-773.	1-29
A	CA 2,134,744 (Rhee, W. M. et al.) 4 May 1995 (04.05.1995)	1-29
A	CA 2,286,718 (Peyman, G. A.) 5 November 1998 (05.11.1998)	1-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/CA2005/001240

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date	
US4581030	08-04-1986	US4505855	19-03-1985	
US4223984	23-09-1980	NONE		
US2003018123	23-01-2003	RU2190841 C1	10-10-2002	
CA2134744	04-05-1995	AT157351 T AT168708 T AT197058 T AT255918 T AU638687 B2 AU668265 B2 AU677789 B2 AU698233 B2 AU1507595 A AU4660989 A AU4662093 A AU5522994 A CA2003538 A1 CA2115967 A1 CA2143923 A1 CA2172906 A1 DE59403818 D1 DE68928754 D1 DE68928754 T2 DE69519124 D1 DE69519124 T2 DE69630990 D1 DE69630990 T2 DK612723 T3 EP0444157 A1 EP0612723 A1 EP0648239 A1 EP0656214 A1 EP0656215 A1 EP0680990 A1 EP0697218 A2 EP0747066 A2 ES2107698 T3 ES2119743 T3 ES2211923 T3 FI114467 B1 GR3024855 T3 HU70535 A2 IL108697 A JP2505312 B2 JP3554352 B2 JP4502027 T JP7278203 A JP7278312 A JP8053548 A JP8502082 T JP9099052 A JP2004189755 A NO300322 B1 NZ250919 A TW420659 B	15-09-1997 15-08-1998 15-11-2000 15-12-2003 08-07-1993 26-04-1996 08-05-1997 29-10-1998 09-11-1995 12-06-1990 31-01-1994 25-08-1994 21-05-1990 21-08-1994 03-11-1995 08-12-1996 02-10-1997 27-08-1998 14-01-1999 23-11-2000 17-05-2001 22-01-2004 30-12-2004 30-03-1998 04-09-1991 31-08-1994 19-04-1995 07-06-1995 07-06-1995 08-11-1995 21-02-1996 11-12-1996 01-12-1997 16-10-1998 16-07-2004 29-10-2004 30-01-1998 30-10-1995 16-07-2000 05-06-1996 18-08-2004 09-04-1992 24-10-1995 24-10-1995 27-02-1996 05-03-1996 15-04-1997 08-07-2004 12-05-1997 26-01-1996 01-02-2001	

Continued on Supplemental Page 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/001240

Continued from Information on Patent Family Members (page 5)

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
		US5162430	10-11-1992
		US5264214	23-11-1993
		US5292802	08-03-1994
		US5304595	19-04-1994
		US5306500	26-04-1994
		US5308889	03-05-1994
		US5324775	28-06-1994
		US5328955	12-07-1994
		US5376375	27-12-1994
		US5413791	09-05-1995
		US5446091	29-08-1995
		US5470911	28-11-1995
		US5475052	12-12-1995
		US5476666	19-12-1995
		US5510121	23-04-1996
		US5510418	23-04-1996
		US5523348	04-06-1996
		US5527856	18-06-1996
		US5543441	06-08-1996
		US5550187	27-08-1996
		US5550188	27-08-1996
		US5565519	15-10-1996
		US5614587	25-03-1997
		US5643464	01-07-1997
		US5744545	28-04-1998
		US5786421	28-07-1998
		US5800541	01-09-1998
		US5866610	02-02-1999
		US5936035	10-08-1999
		WO9005755 A1	31-05-1990
		WO9401483 A1	20-01-1994
		ZA9401119 A	30-08-1994
CA2286718	05-11-1998	AU739297 B2	11-10-2001
		AU772492 B2	29-04-2004
		AU778310 B2	25-11-2004
		AU3713400 A	21-09-2000
		AU3713500 A	21-09-2000
		AU6456798 A	24-11-1998
		BR0008601 A	26-12-2001
		BR0008624 A	26-12-2001
		BR9809289 A	04-07-2000
		CA2364038 A1	08-09-2000
		CA2366022 A1	08-09-2000
		CN1253484 A	17-05-2000
		CN1342095 A	27-03-2002
		CN1360486 A	24-07-2002
		EP1014872 A1	05-07-2000
		EP1158936 A1	05-12-2001
		EP1159033 A1	05-12-2001
		JP2000513986 T	24-10-2000
		JP2002537895 A	12-11-2002
		JP2002537912 A	12-11-2002
		MXPA01008759 A	14-07-2003
		MXPA01008760 A	14-07-2003

Continued on Supplemental Page 7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/001240

Continued from Supplemental Page 6

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
		US5722971	03-03-1998
		US5919185	06-07-1999
		US5964748	12-10-1999
		US6063073	16-05-2000
		US6197019 B1	06-03-2001
		US6203538 B1	20-03-2001
		US6217571 B1	17-04-2001
		US6221067 B1	24-04-2001
		US6280470 B1	28-08-2001
		US2001027314 A1	04-10-2001
		US2001034516 A1	25-10-2001
		WO0051526 A1	08-09-2000
		WO0051682 A1	08-09-2000
		WO9848715 A1	05-11-1998